Merck to Showcase Advances in the Science of Cancer With New

First-in-human data for potential first-in-class anti-CEACAM5 ADC with topoisomerase 1 inhibitor payload, M9140, in treatment of metastatic colorectal cancer to be featured in oral presentation

Related Keywords

United Kingdom , Canada , University Of Chicago , Illinois , United States , China , Japan , San Francisco , California , Chicago , American , Chinese , Kevin Harrington , Eli Lilly , Jonathan Schoenfeld , Serono , Dana Farber Cancer Institute , Institute Of Cancer Research , European Commission , University Of Chicago Medicine , Head Of Development Unit , Ddriver Clinical Trial Program , American Society Of Clinical Oncology , University Of California , Drug Administration , W Chicago City Center , Clinical Oncology , Annual Meeting , Victoria Zazulina , Development Unit , Clinical Trials , Solid Tumors , Cancer Research , Sari Rosenberg , Chicago Medicine , Sue Yom , Chicago City Center , Adams Street , Tumor Biology , Saturday June , Monday June , Neck Cancer , Sunday June , Genitourinary Cancer Kidney , Gastrointestinal Cancer Colorectal , Lung Cancer Non Small Cell Metastatic , Clinical Trial Program , Product Characteristics , Ihr Portfolio ,